Navigation Links
Pharmacyclics Announces Subscription Price for Rights Offering
Date:7/15/2009

s listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us athttp://www.pharmacyclics.com.

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our expectations and beliefs regarding our future results or performance. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "should", "would", "project", "plan", "predict", "intend" and similar expressions are intended to identify such forward-looking statements. Our actual results could differ materially from those projected in the forward-looking statements. Additionally, you should not consider past results to be an indication of our future performance. For a discussion of the risk factors and other factors that may affect our results, please see the Risk Factors section of our filings with the Securities and Exchange Commission, including our annual report on Form 10-K and quarterly reports on Form 10-Q. We do not intend to update any of the forward-looking statements after the date of this announcement to conform these statements to actual results, to changes in management's expectations or otherwise, except as may be required by law.


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference
2. Pharmacyclics Files Registration Statement for Rights Offering
3. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
4. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
5. Pharmacyclics Secures $5.0 Million in Debt Financing
6. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
7. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
8. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
9. Pharmacyclics Announces It Received Nasdaq Notification
10. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
11. Blue Marble Energy Corp. Announces Successful Close of Series A Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... PARIS and NEW YORK ... data from its open-label pilot study of mazindol in ... Design, Development and Therapy in December 2014 . ... of mazindol in children with attention deficit/hyperactivity disorder" ( ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) ...
(Date:12/22/2014)... 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, ... today announced positive topline safety and tolerability ... of SYN-004, the Company,s investigational oral beta-lactamase ... difficile (C. difficile) infection, antibiotic-associated diarrhea ...
(Date:12/22/2014)... 22, 2014  Alternative Energy & Environmental Solutions, ... signed a letter of intent to acquire BioTechPharma ... patented a nanotechnology-based development platform used to create ... rapid on-site collection and testing to identify infectious ... in an immediate, non-invasive and cost-effective manner. ...
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
Breaking Biology Technology:Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5ALNE Announces Intention To Acquire BioTechPharma 2WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2
... Magellan Biosciences, a global manufacturer of products designed ... labor intensive, announced that its Vice President of Business ... featured speaker at the Medicaid Health Plans of America ... takes place tomorrow in Washington, DC. Mr. De Jesus ...
... 17, 2011 Anaphore Inc. today announced that Katherine Bowdish, ... overview at the 13th Annual C21 BioVentures conference. The presentation ... at The Meritage Resort in Napa, Calif.   ... is developing a new class of protein pharmaceuticals to address ...
... PERTH, Australia, May 17, 2011 Australian supplier of ... an exclusive distributor agreement with a leading Japanese Life ... Taiwan, China and South Korea. Headquartered in ... in the chemical, pharmaceutical and biotechnology industries and have ...
Cached Biology Technology:Magellan Biosciences to Present at Medicaid Health Plans of America Center for Best Practices First Annual Awards Forum 2Magellan Biosciences to Present at Medicaid Health Plans of America Center for Best Practices First Annual Awards Forum 3Magellan Biosciences to Present at Medicaid Health Plans of America Center for Best Practices First Annual Awards Forum 4Magellan Biosciences to Present at Medicaid Health Plans of America Center for Best Practices First Annual Awards Forum 5Magellan Biosciences to Present at Medicaid Health Plans of America Center for Best Practices First Annual Awards Forum 6Anaphore to Present Company Overview with Focus on Atrimer Technology Platform at 13th Annual C21 BioVentures Conference 2Epichem and AR Brown Sign Exclusive Distribution Agreement for Japan, Taiwan, China and South Korea 2Epichem and AR Brown Sign Exclusive Distribution Agreement for Japan, Taiwan, China and South Korea 3
(Date:12/5/2014)... , Dec. 4, 2014 Increased emphasis ... investments in new testing and inspection technologies. The ... rise to a range of innovative test solutions. ... of Generation Y, which is generally more inclined ... result, product development strategies of test equipment vendors ...
(Date:12/4/2014)... 3, 2014  Crossmatch™, a leading provider of ... DigitalPersona ® Pro Enterprise software and U.are.U ... throughout First Bank branch locations in ... and Virginia. First Bank, a progressive community ... North Carolina , selected the Crossmatch biometrics-based ...
(Date:12/3/2014)... Dec. 2, 2014 As part of our ... Technologies is pleased to announce the release of a ... to collect the workforce data that they need. ... been left by existing readers. Many such devices have ... and modern technology. Older models force users to navigate ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2
... COLUMBIA, Mo. Studies show the incidence of diabetes in ... Now, University of Missouri veterinarians have changed the way veterinarians ... monitor glucose in humans. Dogs are susceptible to type ... in their bloodstream because their bodies do not produce enough ...
... is often referred to as the land of opportunity. ... of opportunity." NJIT gave him the opportunity, for instance, ... distinguished professor in the department of physics. Naqvi started the ... his research recently helped him win a Goldwater Scholarship ...
... Ohio Mosquitoes make proteins to help them handle the ... blood meals, a new study has found. The mosquito,s ... finding warm-blooded hosts, avoiding detection, penetrating tough skin and evading ... a human hand. Until now, the stress of the ...
Cached Biology News:MU researchers pioneer animal diabetes treatment 2Third brother wins gold at NJIT 2Study shows how mosquitoes handle the heat of a hot blood meal 2Study shows how mosquitoes handle the heat of a hot blood meal 3
... product has been developed to significantly increase ... proteins. Stability is increased at room ... centigrade. This product is subjected to ... or azide. This formulation insures consistently ...
This unique buffer provides a gentle method for removal of primary and secondary antibodies to allow several reprobings on the same membrane. Gentle buffer will not alter the antigen for subsequent i...
... The 500 optimization kit is for fine-tuning ... interest. The kit is recommended when you ... system. The kit includes 0.25 g each ... micrometer diameter gold microcarriers, 100 each of ...
... Serial Analysis of Gene Expression (SAGE) ... technology. Agencourt offers a cost-effective outsourcing ... and LongSAGE libraries. Agencourt's SAGE sequencing ... project turnaround and long Phred20 read ...
Biology Products: